Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People

Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Retrieved on: 
Thursday, December 22, 2022
Oncology, Health, Hospitals, Genetics, Pharmaceutical, Biotechnology, HDT, Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, Standard of care, Daiichi Sankyo, ASCT, SOC, Multimedia, B-cell lymphoma, Non-Hodgkin lymphoma, CAR, Patient, MHLW, CD19, Standard, EFS, TSE, Pharma, Doctor of Philosophy, Pharmaceutical industry, Health, Axicabtagene ciloleucel

Yescarta should be used only in patients who have not received prior transfusion of CAR T-cells targeted at CD19 antigen.

Key Points: 
  • Yescarta should be used only in patients who have not received prior transfusion of CAR T-cells targeted at CD19 antigen.
  • Although approximately 60% of newly diagnosed LBCL patients will respond to the initial treatment with chemotherapy, 40% will relapse or will not respond and need second-line treatment.
  • Yescarta is now approved for the initial treatment of R/R LBCL patients in Japan.
  • Kite’s manufacturing facility in El Segundo, California, U.S., has been approved by Japanese regulatory authorities to commence manufacturing Yescarta for the Japan market in 2023.

Wearable Medical Devices Ascendant Regardless of COVID-19

Retrieved on: 
Wednesday, October 27, 2021
Crypto, Sleep, Alternative, Diabetes, Play, Climate change, Insulin, Dexcom, Philips, Communication, Move, Marketing, Computer, COVID-19, American Diabetes Association, Health, Acquisition, Prevalence, Heart rate, AI, Research, Diagnosis, Publishing, Google, Mining, Type 1, Biotelemetry, Internet, Solution, ACO, CTO, Water, Cannabis, Ecosystem, Disclosure, Industry, Conditional sentence, Risk, Social media, Medicare, CEO, GBT, Awareness, Clean technology, IOT, News, Alphabet Inc., Artificial intelligence, Sale, G6, IR, CONTOUR, CGM, Patient, Policy, Time, OTC Markets Group, Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, Renewable energy, Verily, API, University Hospitals Cleveland Medical Center, Medical device, Satellite navigation device

With ongoing developments in areas such as Internet of things (IoT) and Artificial Intelligence (AI), and given the backdrop of the COVID-19 pandemic, the demand for mobile or wearable medical devices is, understandably, on the rise.

Key Points: 
  • With ongoing developments in areas such as Internet of things (IoT) and Artificial Intelligence (AI), and given the backdrop of the COVID-19 pandemic, the demand for mobile or wearable medical devices is, understandably, on the rise.
  • This category encompasses wearable therapeutic devices, wearable monitoring and diagnostic devices, and health and fitness devices.
  • According to the report's summary, demand for wearable medical devices is expected to be driven by a "high prevalence of chronic diseases," and an "increasing geriatric population."
  • So while future research might indicate more clearly the impact of COVID-19 on the market, it is clear that demand for wearable medical devices is well established and growing regardless.

RIBOMIC Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration at the Retina Society 2021 Meeting

Retrieved on: 
Thursday, September 30, 2021
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Retina, Severe cognitive impairment, Advertising, Retinal degeneration, Therapy, Patient, AMD, Data, Choroidal neovascularization, Standard of care, Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, CEO, Growth factor, Company, Standard, FGF2, JST, AES, Injection, Blood, Safety, Fibrosis, Uniloc USA, Inc. v. Microsoft Corp., TOFU, AE, Pharmaceutical industry, Medical device, RBM-007, wet Age-related Macular Degeneration, RBM-007, WET AGE-RELATED MACULAR DEGENERATION

The TOFU study remains masked and all of the interim data from the trial are on a masked basis (RBM-007 arm, RBM-007+Eylea arm, and Eylea arm combined).

Key Points: 
  • The TOFU study remains masked and all of the interim data from the trial are on a masked basis (RBM-007 arm, RBM-007+Eylea arm, and Eylea arm combined).
  • The remainder of the subjects are at different time-points in the trial depending on their start date.
  • Wet (exudative) age-related macular degeneration, is the leading cause of blindness in the United States and Europe.
  • "RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.